We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Immunogenomic Landscape of Hematological Malignancies Mapped

By LabMedica International staff writers
Posted on 20 Jul 2020
Print article
Image: The Immunogenomic Landscape of Hematological Malignancies (Photo courtesy of Helsinki University Hospital).
Image: The Immunogenomic Landscape of Hematological Malignancies (Photo courtesy of Helsinki University Hospital).
The reaction of the body's immune system against cancer can be thought of as a cycle. Cancer cells contain proteins that differ from proteins in other tissue. Their components, known as antigens, have to be presented to the T cells of the immune system by the cancer cells.

When they identify antigens, T cells become active and start to destroy cancer cells, which make the latter release more antigens, enhancing the immune response further. In addition to T cells, natural killer (NK) cells have the ability to destroy cells. In immunotherapies, the immune system is therapeutically activated by boosting different stages of the cycle.

A large team of medical scientists collaborating with the Helsinki University Hospital (Helsinki, Finland) integrated over 8,000 transcriptomes and 2,000 samples with multilevel genomics of hematological cancers to investigate how immunological features are linked to cancer subtypes, genetic and epigenetic alterations, and patient survival, and validated key findings. They mapped the immune landscape of hematological malignancies in a dataset covering more than 10,000 patients to identify drug targets and patient groups which could potentially benefit from immunotherapies.

The team reported that infiltration of cytotoxic lymphocytes was associated with TP53 and myelodysplasia-related changes in acute myeloid leukemia, and activated B cell-like phenotype and interferon-γ response in lymphoma. CIITA methylation regulating antigen presentation, cancer type-specific immune checkpoints, such as V-domain Ig suppressor of T cell activation (VISTA) in myeloid malignancies, and variation in cancer antigen expression further contributed to immune heterogeneity and predicted survival.

The investigators found that in certain subtypes of acute myeloid leukemia, DNA methylation had epigenetically silenced antigen presentation. A drug that inhibits DNA methylation restored the expression of antigen-presenting proteins in laboratory tests. As the drug is already used to treat acute myeloid leukaemia, it could potentially increase the efficiency of immunotherapies through combined use.

Satu Mustjoki, MD, PhD, a Professor of Translational Hematology and senior author of the study, said, “The extensive survey of the immunogenomic features of hematological malignancies carried out in the study helps scientists and doctors target immunotherapies at the patient groups that gain the most benefit as well as understand the factors that have a potential impact on the efficacy of therapies.”

The authors concluded that their study provided a resource linking immunology with cancer subtypes and genomics in hematological malignancies. The study was published on July 9, 2020 in the journal Cancer Cell.

Related Links:
Helsinki University Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.